Atlas Trials

A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous AGX-201 for Migraine Prophylaxis

Clinical trial NCT02021474 · UNKNOWN

Trial details

NCT number
NCT02021474
Sponsor
AgoneX Biopharmaceuticals, Inc.
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Migraine Prophylaxis
Start date
2022-10-01
Primary completion
2023-07-01
Enrollment
130

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.